Xenon Pharmaceuticals Inc. (XENE): Biotechnology Value Fund Adds More Shares

Published on September 12, 2016 at 12:43 pm by Insider Monkey Staff in Hedge Funds,News

Page 1 of 10

Mark Lampert‘s Biotechnology Value Fund reported raising its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to 3.11 million shares, which account for 17.9% of the company’s outstanding stock, via a newly-amended 13G filing released by the Securities and Exchange Commission. Previously, the fund held 1.78 million shares or 12.3% of Xenon’s outstanding stock, according to its 13F filing for the June 30 reporting period.

As the name denotes it, Xenon Pharmaceuticals is a clinical stage biopharmaceutical company that develops various therapeutics for orphan indications. Recently, the company made a $30 million public offering of common shares, priced at $7.50 per share. Year-to-date, Xenon Pharmaceuticals’ stock is down by 4.48%. In its latest financial report, for the second quarter of 2016, the company disclosed revenue of $0.4 million and a basic loss per share of $0.42, compared to a revenue of $4.04 million and earnings per share of $0.08, for the corresponding period of the prior year.

medication, pharmacist, shelf, care, pharmaceutical, medical, day, drug, clinic, medicament, drugstore, treatment, ill, smiling, medicine, pharmaceutics, of, hospital,

wavebreakmedia/Shutterstock.com

Among the hedge funds from Insider Monkey’s database, seven were long Xenon Pharmaceuticals (NASDAQ:XENE) at the end of June, down from eight a quarter earlier. Some of the bullish investors contained Steve Cohen’s Point72 Asset Management, with a position valued at $2.12 million, and Jim Simons’ Renaissance Technologies, which held a position worth around $286,000.

Follow Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Follow Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Biotechnology Value Trading Fund OS	262,664	262,664	262,664	1.5%
BVF Partners OS Ltd	262,664	262,664	262,664	1.5%
BVF Partners	3,108,905	3,108,905	3,108,905	17.9%
BVF Inc	3,108,905	3,108,905	3,108,905	17.9%
Mark N. Lampert	3,108,905	3,108,905	3,108,905	17.9%

Mark Lampert

Biotechnology Value Fund / BVF Inc

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 10 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. 3)1

Xenon Pharmaceuticals Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

98420N 10 5

(CUSIP Number)

September 8, 2016

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

_______________

1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 10

Next >>